Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.46
HSP's Cash to Debt is ranked higher than
55% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.07 vs. HSP: 0.46 )
HSP' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 0.46

Equity to Asset 0.50
HSP's Equity to Asset is ranked higher than
60% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. HSP: 0.50 )
HSP' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.69
Current: 0.5

0.34
0.69
Interest Coverage 6.04
HSP's Interest Coverage is ranked higher than
50% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 236.52 vs. HSP: 6.04 )
HSP' s 10-Year Interest Coverage Range
Min: 0.19   Max: 9999.99
Current: 6.04

0.19
9999.99
F-Score: 7
Z-Score: 4.39
M-Score: -2.77
WACC vs ROIC
10.90%
9.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.45
HSP's Operating margin (%) is ranked higher than
76% of the 1104 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. HSP: 10.45 )
HSP' s 10-Year Operating margin (%) Range
Min: 0.41   Max: 16.17
Current: 10.45

0.41
16.17
Net-margin (%) 7.46
HSP's Net-margin (%) is ranked higher than
75% of the 1104 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.42 vs. HSP: 7.46 )
HSP' s 10-Year Net-margin (%) Range
Min: -0.23   Max: 11.4
Current: 7.46

-0.23
11.4
ROE (%) 10.41
HSP's ROE (%) is ranked higher than
78% of the 1133 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. HSP: 10.41 )
HSP' s 10-Year ROE (%) Range
Min: -0.31   Max: 24.74
Current: 10.41

-0.31
24.74
ROA (%) 5.23
HSP's ROA (%) is ranked higher than
75% of the 1166 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. HSP: 5.23 )
HSP' s 10-Year ROA (%) Range
Min: -0.16   Max: 13.13
Current: 5.23

-0.16
13.13
ROC (Joel Greenblatt) (%) 17.24
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.41 vs. HSP: 17.24 )
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.67   Max: 53.84
Current: 17.24

0.67
53.84
Revenue Growth (3Y)(%) 2.20
HSP's Revenue Growth (3Y)(%) is ranked higher than
65% of the 941 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. HSP: 2.20 )
HSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.9   Max: 12.4
Current: 2.2

-0.9
12.4
EBITDA Growth (3Y)(%) 29.60
HSP's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 840 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. HSP: 29.60 )
HSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.3   Max: 29.6
Current: 29.6

-32.3
29.6
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HSP Guru Trades in Q1 2014

Jim Simons 151,800 sh (+284.30%)
Mario Gabelli 153,770 sh (+30.68%)
Vanguard Health Care Fund 8,375,170 sh (+22.69%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Brian Rogers Sold Out
Richard Snow Sold Out
Jeff Auxier 205,530 sh (-5.75%)
John Rogers 4,127,850 sh (-11.62%)
Paul Tudor Jones 10,800 sh (-26.41%)
Steven Cohen 17,130 sh (-55.51%)
» More
Q2 2014

HSP Guru Trades in Q2 2014

Mario Gabelli 204,370 sh (+32.91%)
Jim Simons 182,900 sh (+20.49%)
Robert Bruce 10,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Michael Price 400,000 sh (unchged)
Jeff Auxier 181,463 sh (-11.71%)
John Rogers 3,130,809 sh (-24.15%)
Paul Tudor Jones 7,700 sh (-28.70%)
» More
Q3 2014

HSP Guru Trades in Q3 2014

Joel Greenblatt 313,242 sh (New)
Paul Tudor Jones 24,894 sh (+223.30%)
Jim Simons 323,100 sh (+76.65%)
Mario Gabelli 254,870 sh (+24.71%)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
John Rogers 2,433,369 sh (-22.28%)
Jeff Auxier 127,307 sh (-29.84%)
» More
Q4 2014

HSP Guru Trades in Q4 2014

Jim Simons 631,695 sh (+95.51%)
Mario Gabelli 352,370 sh (+38.25%)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 126,907 sh (-0.31%)
Vanguard Health Care Fund 7,966,970 sh (-4.87%)
John Rogers 2,311,309 sh (-5.02%)
Paul Tudor Jones 19,798 sh (-20.47%)
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Hospira Inc

John Rogers Comments on Hospira Inc. - Jul 25, 2013

Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.

From John RogersAriel Fund Second Quarter 2013 Commentary.


Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 45.00
HSP's P/E(ttm) is ranked higher than
75% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 63.00 vs. HSP: 45.00 )
HSP' s 10-Year P/E(ttm) Range
Min: 8.48   Max: 133.97
Current: 45

8.48
133.97
Forward P/E 27.55
HSP's Forward P/E is ranked higher than
78% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HSP: 27.55 )
N/A
PE(NRI) 44.90
HSP's PE(NRI) is ranked higher than
78% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.60 vs. HSP: 44.90 )
HSP' s 10-Year PE(NRI) Range
Min: 8.48   Max: 135
Current: 44.9

8.48
135
P/B 4.50
HSP's P/B is ranked higher than
63% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. HSP: 4.50 )
HSP' s 10-Year P/B Range
Min: 1.52   Max: 5.83
Current: 4.5

1.52
5.83
P/S 3.35
HSP's P/S is ranked higher than
66% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. HSP: 3.35 )
HSP' s 10-Year P/S Range
Min: 0.99   Max: 3.4
Current: 3.35

0.99
3.4
PFCF 64.40
HSP's PFCF is ranked higher than
77% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HSP: 64.40 )
HSP' s 10-Year PFCF Range
Min: 8.32   Max: 203.78
Current: 64.4

8.32
203.78
POCF 22.76
HSP's POCF is ranked higher than
84% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.09 vs. HSP: 22.76 )
HSP' s 10-Year POCF Range
Min: 5.95   Max: 50.76
Current: 22.76

5.95
50.76
EV-to-EBIT 34.23
HSP's EV-to-EBIT is ranked higher than
77% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.34 vs. HSP: 34.23 )
HSP' s 10-Year EV-to-EBIT Range
Min: -1403.5   Max: 508.2
Current: 34.23

-1403.5
508.2
Shiller P/E 74.50
HSP's Shiller P/E is ranked higher than
75% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HSP: 74.50 )
HSP' s 10-Year Shiller P/E Range
Min: 12.55   Max: 75.13
Current: 74.5

12.55
75.13
Current Ratio 2.27
HSP's Current Ratio is ranked higher than
71% of the 1025 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.23 vs. HSP: 2.27 )
HSP' s 10-Year Current Ratio Range
Min: 2.05   Max: 3.03
Current: 2.27

2.05
3.03
Quick Ratio 1.40
HSP's Quick Ratio is ranked higher than
66% of the 1025 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. HSP: 1.40 )
HSP' s 10-Year Quick Ratio Range
Min: 1.2   Max: 2.01
Current: 1.4

1.2
2.01
Days Inventory 144.51
HSP's Days Inventory is ranked higher than
69% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 141.94 vs. HSP: 144.51 )
HSP' s 10-Year Days Inventory Range
Min: 47.38   Max: 139.51
Current: 144.51

47.38
139.51
Days Sales Outstanding 49.22
HSP's Days Sales Outstanding is ranked higher than
87% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.70 vs. HSP: 49.22 )
HSP' s 10-Year Days Sales Outstanding Range
Min: 43.91   Max: 59.38
Current: 49.22

43.91
59.38

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.00
HSP's Price/Tangible Book is ranked higher than
61% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. HSP: 7.00 )
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04   Max: 20.95
Current: 7

3.04
20.95
Price/DCF (Projected) 3.10
HSP's Price/DCF (Projected) is ranked higher than
84% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HSP: 3.10 )
HSP' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 2.2
Current: 3.1

0.91
2.2
Price/Median PS Value 1.70
HSP's Price/Median PS Value is ranked higher than
65% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. HSP: 1.70 )
HSP' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 1.35
Current: 1.7

0.61
1.35
Price/Graham Number 3.70
HSP's Price/Graham Number is ranked higher than
78% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HSP: 3.70 )
HSP' s 10-Year Price/Graham Number Range
Min: 2.02   Max: 3.97
Current: 3.7

2.02
3.97
Earnings Yield (Greenblatt) 2.90
HSP's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1150 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. HSP: 2.90 )
HSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10
Current: 2.9

0.2
10
Forward Rate of Return (Yacktman) -4.82
HSP's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.47 vs. HSP: -4.82 )
HSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.6   Max: 18.4
Current: -4.82

-1.6
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany,
Hospira Inc was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.
» More Articles for HSP

Headlines

Articles On GuruFocus.com
John Rogers' Ariel Fund Q1 2015 Commentary Apr 17 2015 
Weekly 52-Week Highs Highlight: SIAL, GIS, TJX, HSP Mar 30 2015 
Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
Feeling Good With This Med Company Jan 20 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 


More From Other Websites
Four Tips for Buying the Dip Apr 18 2015
James Pallotta’s Raptor Capital Hits Homerun with Hospira, Inc. (HSP) Apr 17 2015
Need to change the laws on corporate tax: Pfizer CEO Apr 16 2015
Banks see talent flee amid healthcare M&A boom Apr 14 2015
Will Pharmaceutical Sales Drive J&J (JNJ) Earnings Again? - Analyst Blog Apr 13 2015
Hope for Greater Access for Patients to Biosimilar Medicines Apr 13 2015
Hope for Greater Access for Patients to Biosimilar Medicines Apr 13 2015
The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog Apr 10 2015
Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog Apr 08 2015
Hospira hit with further FDA scrutiny after $17 billion Pfizer deal Apr 08 2015
Hospira to Announce First-Quarter 2015 Results on April 28, 2015 Apr 07 2015
Hospira to Announce First-Quarter 2015 Results on April 28, 2015 Apr 07 2015
Boston Scientific Boosts Endoscopy Business, Buys Xlumena - Analyst Blog Apr 07 2015
Hospira hit with another FDA warning letter Apr 07 2015
Hospira gets FDA warning letter for Italian facility Apr 07 2015
HOSPIRA INC Files SEC form 8-K, Other Events Apr 07 2015
How Actavis and Allergan Merger May Boost Branded Business Apr 03 2015
The Medicines Co. Settles Angiomax Patent Dispute with Sun - Analyst Blog Apr 02 2015
These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter Apr 02 2015
North American Brands’s Position of Strength Apr 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK